No Data
No Data
Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rating
Editas Medicine Is Maintained at Perform by Oppenheimer
Editas Medicine Is Maintained at Perform by Oppenheimer
Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $12
Oppenheimer analyst Jay Olson maintains $Editas Medicine(EDIT.US)$ with a hold rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 44.2% and a t
BofA Securities Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $13
BofA Securities analyst Greg Harrison maintains $Editas Medicine(EDIT.US)$ with a hold rating, and adjusts the target price from $15 to $13.According to TipRanks data, the analyst has a success rate o
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine (EDIT) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was "well-tolerated" and had a safety profile c
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of total hemoglobin with a mean within t
No Data